Lorlatinib, is currently the only a listing of the three generations of ALK - TKIs drugs, phase I clinical study has shown its good therapeutic effect. In 2018, Lorlatinib for treatment of ALK positive in NSCLC patients with lung cancer cohort study...

In the summer of common disease have? The doctor said to healthy living small plait, summer heat, heat stroke, and a peak period of intestinal infectious diseases, although these fatal diseases is not easy, but also cannot ignore, attaches great impo...

MET gene (chromosome 7 long arm, contains 21 exon) coding c - MET protein is hepatocyte growth factor (HGF) tyrosine kinase receptor, HGF and c - MET with activation of downstream signaling pathways, promote cell proliferation, growth, migration, and...

Abstract: on May 6, 2020, the United States food and drug administration (FDA) approved the karma for (Tabrecta Capmatinib) that is used to treat carry MET gene exon 14 jumping mutation of advanced NSCLC. On May 6, 2020, the United States food and dr...

On September 21, 2020, OncLive published a stage I CHRYSALIS research results, evaluate the Amivantamab, - 61186372) joint lazertinib (YH25448) in the initial and the west for late (Tagrisso) resistance of EGFR mutations in non-small cell lung cancer...